A Pioneering Biotech Hedge Fund
Investing in innovative life science companies with the novel Integrated BioSci Investing!
About Evergrowth BioHealthcare Capital
Managed by Evergrowth BioHealthcare Advisors, Evergrowth BioHealthcare Capital is a Delaware-incorporated emerging growth biotech hedge fund with a unique edge in binary event forecasting. This entails either an FDA approval or a significant clinical data release, which tends to catalyze substantial share price movements.
The fund strategically invests in clinical-stage and early product-stage public biotech equities. Positioned to outperform market benchmarks such as the Dow Jones Industrial Average (INDU), Nasdaq Biotechnology Index (NBI), and S&P500 (SPY) in the long term, we aim to deliver superior returns for our investors.
Why Choose Evergrowth BioHealthcare Capital?
01
Deep Understanding of Biotech Industry
Our team of seasoned professionals has a deep understanding of the biotech industry, enabling us to identify promising investment opportunities in innovative biotech companies.
02
Data-Driven Approach
We utilize a data-driven approach to identify and evaluate investment opportunities in the biotech sector, providing our clients with a diversified portfolio and competitive returns.
03
Expertise in Biotech and Finance
By combining our expertise in biotech and finance, we offer a unique investment solution that seeks to capture the potential of medical advancements and generate attractive returns for our clients.
Investment Terms
Key terms include a minimum investment of $50,000, a management fee of 2%, a performance fee of 20%, a lockup period of 1095 days, and a 30-day notice to withdrawal. Our fund, with an open status, invites potential investors. We are open to custom terms negotiation.
Service Providers
We partner with Spicer Jeffries LLP, a leading tax and auditing firm in Colorado that services asset managers. Our hedge fund administration is handled by Repool Inc., an innovative company in New York City. Legal expertise is provided by Berger McDermott LLP, a Delaware law practice specializing in hedge funds.
Management Team
Our Board of Directors includes Dr. Harvey Tran and Mr. David Newman. Dr. Tran also serves as CEO and Chief Investment Officer. Our management team also comprises a Medical/Scientific Advisory Board and a Technology/Business Development Advisory Board.
Board of Directors
Harvey Tran, MD, MS
Chairman of the Board
Dr. Tran is primarily responsible for the implementation and execution of the Fund’s investment strategy. Dr. Tran is a physician executive, scientist, mentor, and entrepreneur. In 2017, Dr. Tran founded Integrated BioSci Investing, a biotech investment research and consulting business.
Since 2019, Dr Tran has served as a consultant for several pharmaceutical companies through which he provided guidance on investor relations and medical expertise. In 2020, Dr. Tran founded High Performance Healthcare, a company focused on the acquisition of home healthcare agencies, and served as a CEO and Board member. Dr. Tran is a member of Spru Ventures, a venture capitalist group that focuses on alternative investments. He also served as Vice President of Canterbury Homeowners Association.
Dr. Tran earned his MS at the world-renowned Columbia University College of Physicians and Surgeons in New York City. He completed his MD training at The Brody School of Medicine in 2013.
David Newman, JD
Board Member
Mr. Newman is a securities lawyer with over 30 years of enforcement and regulatory experience. Mr. Newman is in private practice and serves as a consultant with the Bates Group.
From 1999 to 2022, Mr. Newman served as a counsel for the Financial Industry Regulatory Authority’s (FINRA) Enforcement Department where he oversaw all aspects of Enforcement cases, including direct involvement in investigations, negotiating settlements, and litigating cases.
From 1990 to 1999, Mr. Newman served as Trial Counsel and Special Counsel with the Securities and Exchange Commission where he investigated and litigated cases involving violations of the federal securities laws. Mr. Newman also served as a Judge Advocate with the United States Air Force for 28 years.
Mr. Newman received his BA degree from Boston University and his JD degree from New York Law School.
Executive Leadership
Harvey Tran, MD, MS
Chief Executive Officer, Chief Investment Officer, Fund Trader and Interim Secretary
Medical and Scientific Advisory Board
Van Nguyen, MD, FACC
Chairman of the Medical and Scientific Advisory Board | Board Certified Cardiologist & Medical Director of BayCare Medical Group
Harvey Tran, MD, MS
Columbia University Physician Scientist & Biotech Consultant
My Hong Le, OD
Board
Certified Optometrist
Linh Nguyen, MD
Physician and Electrical Engineer
Alina Hulsey, MD, D.ABA
Board Certified Anesthesiologist
Ngoc Pham, MD
Board Certified Family Physician
Technology & Business Development Advisory Board
Geoffrey Bishop, MA
Anton Andonov
Edoardo Taraschi, MA
David Sawyer
Edward Huynh
Khalid Khatib, MSc
Thanh Le
Fund Founders
Harvey Tran, MD, MS
My Hong Le, OD
Linh Nguyen, MD
Geoffrey Bishop, MA
Van Nguyen, MD, FACC
David Sawyer
Edward Huynh
Edoardo Taraschi, MA
Dorella Perlas, RChE
Anton, Andonov
David Newman, JD
